Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+HER2- Breast Cancer”

614 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 614 results

Testing effectiveness (Phase 2)Looking for participantsNCT05983107
What this trial is testing

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Who this might be right for
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 102
Testing effectiveness (Phase 2)Active Not RecruitingNCT05262400
What this trial is testing

Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Who this might be right for
Breast CancerSolid Tumors
Pfizer 235
Testing effectiveness (Phase 2)UnknownNCT06470672
What this trial is testing

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
Fudan University 32
Large-scale testing (Phase 3)Looking for participantsNCT05891093
What this trial is testing

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Who this might be right for
Breast Cancer
Fudan University 766
Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Testing effectiveness (Phase 2)Looking for participantsNCT04923542
What this trial is testing

SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

Who this might be right for
Brain MetastasesHR+ Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 31
Testing effectiveness (Phase 2)Looking for participantsNCT07492394
What this trial is testing

Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer
Hebei Medical University Fourth Hospital 60
Testing effectiveness (Phase 2)Study completedNCT03054363
What this trial is testing

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
University of Colorado, Denver 42
Testing effectiveness (Phase 2)Study completedNCT06375707
What this trial is testing

First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 74
Large-scale testing (Phase 3)Active Not RecruitingNCT05104866
What this trial is testing

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Who this might be right for
Breast Cancer
AstraZeneca 732
Testing effectiveness (Phase 2)Ended earlyNCT04460430
What this trial is testing

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 12
Not applicableUnknownNCT04852081
What this trial is testing

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Who this might be right for
Breast Cancer Stage IV
Blokhin's Russian Cancer Research Center 1,000
Early research (Phase 1)Ended earlyNCT02964507
What this trial is testing

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Who this might be right for
Neoplasms
GlaxoSmithKline 124
Testing effectiveness (Phase 2)Study completedNCT03988036
What this trial is testing

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

Who this might be right for
Breast Cancer
Women's Cancer Study Group GmbH 46
Testing effectiveness (Phase 2)UnknownNCT05075512
What this trial is testing

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Breast Neoplasm Female
Zhejiang Cancer Hospital 40
Large-scale testing (Phase 3)Active Not RecruitingNCT04055493
What this trial is testing

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Who this might be right for
Breast Cancer Female
Women's Cancer Study Group GmbH 1,684
Not applicableLooking for participantsNCT06106477
What this trial is testing

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer
Medical College of Wisconsin 20
Testing effectiveness (Phase 2)Looking for participantsNCT04348747
What this trial is testing

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Malignant Neoplasm in the BrainMetastatic Triple-Negative Breast Carcinoma+1 more
Roswell Park Cancer Institute 23
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07292207
What this trial is testing

Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer

Who this might be right for
ctDNA MonitoringBreast Cancer
Nagoya City University 30
Testing effectiveness (Phase 2)Study completedNCT00933517
What this trial is testing

Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.

Who this might be right for
Pathological Response Rate
Centre Jean Perrin 62
Next Page